Addictive disorders are common and underdiagnosed in the general medical population. While it is well recognized that alcohol consumption is linked to cancers of the head and neck as well as the large bowel, its association with cancers for which hematopoietic SCT (HSCT) is a modality of treatment is not as clear. Further, the complications of alcohol or other drug addiction in patients undergoing HSCT has not been well studied. However, patients with comorbid substance use disorders (SUDs) are at higher risk for morbidity and mortality while undergoing HSCT due to medical sequelae of SUDs and issues of social support, adherence to treatment plans, and impairment of judgment and decision-making. Behavioral patterns of patients with SUDs are clearly relevant factors to consider in patient selection, management and outcome. We offer a review of the existing literature and recommendations for assessment and management of this patient population.
Many factors contribute to the outcome of cancer patients who receive BM or SCT. Psychiatric and social variables can significantly impact the management, physical and emotional well-being, [1] [2] [3] as well as morbidity and mortality of this patient population. 4 However, there is a paucity of literature available examining the outcomes or consequences substance use disorders (SUDs) have for patients undergoing hematopoietic SCT (HSCT).
There is ample evidence of alcohol's direct toxic effects on the body. Specifically, regarding its effect on the blood and BM, it is known that heavy and chronic alcohol consumption can cause generalized depression of blood cell production. Alcohol use can also produce structurally abnormal blood precursors that cannot mature into functional cells. In addition, alcohol can interfere with the production and function of WBCs that defend against infections by decreasing the ability of neutrophils to bind, ingest and kill bacteria and reduce lymphocytic antibody production, as well as causing a direct toxicity on macrophages and monocytes in the BM. 5, 6 Excessive alcohol use can result in thrombocytopenia due to an indirect effect of liver damage, which decreases the number of factors that are necessary for platelet formation. 6 Excessive and chronic alcohol use also puts patients at risk for additional medical comorbidities. Medical problems commonly seen in patients with alcohol use disorders include hypertension, gastrointestinal bleeding, sleep disorders, major depression, hemorrhagic stroke, cirrhosis of the liver and cancers of the head, neck and gastrointestinal system. 7 There are very few data on the impact of alcoholism or other SUDs in patients receiving HSCT. Chang et al. 8 retrospectively studied the effect that comorbid addictive disorders had on overall survival after undergoing BMT. Although the number of patients in this study was relatively small and included current and past abuse or dependence on a variety of substances (alcohol, marijuana, cocaine and narcotics), the probability of survival among these patients was dramatically reduced compared to a group matched for age, sex and diagnosis. Fifteen of seventeen patients who had SUDs and BMT died within the first year. The causes of death among patients with addictive disorders in this cohort were from sepsis (five), veno-occlusive disease (three), GVHD (two), respiratory disease, hemorrhage, liver failure, hemolytic uremic syndrome and disease recurrence (each one). By comparison, seven patients in the control group died-four from respiratory disease, two from GVH and one secondary to hemorrhage. The authors speculate that subclinical hepatic injury (from i.v. drug use and/or alcohol), alterations in hepatic drug-metabolizing enzymes or pulmonary damage from cigarette smoking may have been causative factors.
In a subsequent study, Chang et al. 9 evaluated a number of medical and psychosocial variables among a cohort of 114 patients with CML undergoing allogeneic HSCT. In this study, although neither cigarette smoking or lifetime SUDs were found to statistically affect 1-year survival, the authors raise the concern that these factors may have contributed to patients' morbidity in other ways, and therefore predisposed individuals to the risks of complications post transplant, such as infection and impairment of liver function.
In a large Italian study, Battaglioli et al. 10 found that in patients with non-Hodgkin's lymphoma, those regarded as 'drinkers' had a 41% increased risk of death, and that an association exists between survival and daily ethanol intake, duration of consumption and cumulative intake, with heavier drinkers having a higher risk of death than nondrinkers. However, treatment modalities for the lymphoma were not addressed in this study, precluding any conclusions with regard to HSCT.
Because the literature in this area is scant, the focus of the remainder of this review will primarily be on alcohol abuse and dependence. However, with regard to behavioral aspects of SUDs, such as lack of social supports, problems with adherence to medical treatments and impairment in judgment due to denial or acute intoxication, the reader can generalize these concerns to patients whose substance of choice is something other than alcohol.
Clinical considerations
According to the National Institute on Alcohol Abuse and Alcoholism, 11 12-month prevalence and population data indicate that approximately 12% of males and 5% of females carry the diagnosis of alcohol abuse or dependence, as defined by Diagnostic and Statistical Manual of Mental Disorders-IV-TR criteria. 12 The incidence of alcoholism or other substance abuse among patients treated with HSCT is unknown, but is likely to be close to that of the general population.
When patients who have various types of cancer become candidates for HSCT, and who have a comorbid SUD, it is critical to regard this diagnosis as one would with any other major illness, understand that it is a chronic progressive disease, can be life-threatening and can also threaten the success and ultimate outcome of the recommended transplantation.
Social stigma and lack of exposure to formal training involving SUDs during medical school or residency contribute to misunderstanding and inadequate treatment in the medical setting. Many physicians believe that use of alcohol or other substances is a problem of weakness, poor moral character or that the substances are used to ameliorate other symptoms such as anxiety or depression but are not a significant medical problem. 13 However, addictive disorders are a group of diseases that involve genetics, neurophysiology, sociology and psychology and requires expert assessment and ongoing treatment to prevent relapse and minimize harm if an exacerbation occurs. A recent study on primary care practices demonstrates that only about 10% of patients with alcohol dependence received the recommended quality of care, including assessment and referral to treatment.
14 A study from Johns Hopkins University Hospital shows that among adult hospital admissions, only 25% of patients on Medicine services were screened for alcoholism, 19% on Neurology services and 23% on Surgery. 15 On the basis of the studies looking at general hospital admissions in the US, 14% of patients between the age of 18 and 44 had chronic illicit substance use. 16 Polednak 17 reviewed the charts of 618 hospitalized adult patients with invasive cancers in Connecticut. This revealed that some information was found in the hospital records in 77.3% of patients, but that, of those patients identified as 'current drinkers' (57.2%) the extent of their use was poorly described, using terms such as 'social' or 'occasional.' This author concludes that better screening is needed for all hospitalized cancer patients to plan for interventions and conduct follow-up studies of prognosis.
Denial
Denial is a major symptom of addictive disorders, making it even more difficult for clinicians to identify and intervene. Without routine, nonjudgmental screening, the diagnosis of SUDs will be missed. To further confound the diagnostic picture, patients with severe medical illness present with an intensity of denial that approaches delusional thinking. In accepting a stigmatizing diagnosis, it adds 'insult to injury' and profoundly affects feelings of hopelessness and helplessness. Compassion from the caregiver allows the patient to be compassionate with him or herself, understanding that he or she is not to blame for having an addiction, but is responsible for accepting treatment to manage it. Referral of the patient for further investigation and treatment, if indicated, validates that transplantation or serious medical illness does not justify continued use of substances that are harmful to the patient's well-being.
HSCT-special issues
On the surface, it may appear that HSCT differs markedly from solid organ transplantation. However, in terms of psychosocial issues that should be assessed and factors that predict a negative outcome, there is remarkable similarity. Limited or nonexistent social support, history of pretransplant noncompliance, presence of an active, untreated mood or other psychiatric disorder, use of avoidance as a coping mechanism and current substance abuse are all potential reasons that a person may not be considered as an appropriate candidate for solid organ transplantation. 13, 18 The current literature with regard to outcomes after HSCT also suggests that the same psychiatric disorders and psychosocial factors are important considerations. [1] [2] [3] Although Hoodin et al., 19 in an analysis of 15 studies of psychosocial factors affecting survival after BMT, conclude that there is no definitive evidence based on the research to date to determine that there is an association between psychosocial factors and survival, the authors do indicate that identifying high-risk individuals before transplant has important implications with regard to enhancement of decision-making and resource allocation that could contribute to increasing the chances of prolonged survival. This literature review also points out the methodological problems with some of the studies that have been performed and suggests that further rigorous research in this area is needed. Another review examining the impact of emotional factors on survival demonstrates that negative emotional factors are associated with worse survival in the long term for SCT patients, but that the converse, that is positive emotional factors (such as optimism about transplant) do not affect survival. 20 Factors including social support, absence of depression and compliance with the treatment plan all are predictors of improved outcome measures in terms of quality of life and well-being, 1-3 which are not trivial considerations.
Social support
Owing to the nature of addiction, many patients who suffer from SUDs have limited social supports and dysfunctional family structures. 21 However, research both with SCT patients as well as patients receiving solid organ transplants suggests that social support is a crucial factor in predicting post transplant quality of life. In a study of 92 SCT patients, all who had comprehensive psychological assessments 1-3 weeks before transplantation, Rodrigue et al. 4 found that social support was a significant predictor both of quality of life and survival status after SCT. Patients who have lower medical risk factors pretransplant, defined as histocompatible matches or those who underwent an autologous transplant, as well as those with higher affective functioning and more stable social support before transplantation were more likely to be living and to have better quality of life at the time of follow-up assessment.
A review of psychosocial risk factors for solid organ transplant patients identified better social support, more compliance with health-care recommendations before transplantation, and less dependency behavior as predictors of post transplant compliance and long-term survival. 18 In a study of 161 candidates for lung, liver and SCTs, Goetzmann et al.
2 used the vulnerability model, which suggests that people who experience stressors are likely to have poor psychological adjustment, to determine which psychosocial variables affect transplant outcomes. They found that cognitive beliefs, affective functioning and social support were good predictors of psychosocial well-being post transplant, and that depression and low social support predict poor life satisfaction at 12 months post transplant. Social support has also been linked with long term affective functioning in SCT patients. Kettmann and Altmaier 3 screened 398 patients receiving allogeneic transplants who participated in a health-related quality of life study of patients for affective functioning and social supports pretransplantation and 1-year post transplant. Of 108 patients still living, 86 participated in the follow-up study. They found that pretransplant depression accounted for 24% of the variance in depression at 1-year post transplantation. When they controlled for age, gender and pretransplant depression, they found that pretransplant social support uniquely accounted for 12% of additional variance in depression at 1-year post transplant. Their findings led them to suggest that lower levels of social support more accurately predicted higher levels of depression 1-year post transplant than pretransplant depression levels. Therefore patients who, because of their active addictive disorders, do not have stable social supports may have shorter overall survival, and are likely to experience poorer quality of life and lower affective functioning post transplant.
Treatment adherence
Noncompliance with medical team recommendations is one of the primary risk factors for patients undergoing any type of transplantation. 18 Patients with SUDs and solid organ transplantation have potential for worse outcomes, in part due to their lack of adherence to medical treatment recommendations. 13 The process of SCT also requires ongoing compliance with complicated medication regimens, including immunosuppressants that help to control potentially life-threatening GVHD. Moreover, medication regimens are often changed repeatedly by the medical team in response to infections, GVHD, or other changes in the patient's condition. SCT patients are also expected to comply with regular outpatient visits and treatments, appointments with their doctor and recommendations of their doctor's colleagues who may cover for them. Thus, patients with addictive disorders who exhibit impaired judgment, and have difficulty following recommendations of medical professionals are at higher risk of developing more medical complications and potentially worse outcomes.
Other concerns BM and SCT patients are at increased risk for developing central nervous system complications. Most frequent complications include infections, cerebrovascular or metabolic events and toxicity from radiation or chemotherapy. 22 Because alcohol has a direct neurotoxic effect on the brain, 23 patients with alcohol use disorders present with a diathesis of neurologic vulnerability including impaired cognition that can affect the patient's ability to understand and process information about the transplantation and follow through with instructions and recommendations. Alcoholism also has associated long-term neurologic sequelae, including Wernicke's encephalopathy, alcoholic cerebellar degeneration, alcoholic dementia and central pontine myelinolysis, neuropathy and myopathy, 23 raising additional concern about cumulative neurologic risk in this population.
Nicotine and cannabis use disorders are also of significant concern in this population due to their direct effect on pulmonary function and risk of infection, including fungal infection. 24 It has been observed that the habitual use of any illicit drug may provide the conditioned associations or disinhibition necessary to lead to use of more destructive substances that may be harder to control. 25 This concept of substitute addictions predicts that if SUDs are not adequately treated in patients receiving transplantation, they are prone to develop dependence on other substances. For example, if a patient has an alcohol dependence disorder and is admitted to the hospital for transplantation where he or she is unable to use alcohol, dependence on narcotics prescribed to address pain may be a substantial risk.
Relapse prevention medications
Relapse prevention medications are recommended as adjunctive treatment to psychotherapeutic interventions. There are three medications currently approved for use in alcohol dependence: disulfiram, acamprosate and naltrexone (available as an oral preparation and a once-a-month extended release injectable). Acamprosate and naltrexone have been demonstrated to reduce craving and help establish abstinence. Naltrexone reduces drinking if relapse occurs. 26 After assessment for any medical contraindications, this group of medications is useful, particularly when started early in the recovery process.
Recommendations for assessment and management
It is recommended that all patients who are being considered for HSCT have a thorough assessment of their psychosocial situation, including support systems and coping skills, and careful assessment and documentation of past history or current diagnosis of substance abuse or dependence. If there are any indicators of current or past psychiatric disorders, referral for a formal psychiatric evaluation should also occur.
Many rating scales have been used in various studies to assess psychosocial factors in patients who have been treated with HSCT. The Transplantation Evaluation Rating Scale (TERS), originally designed to be used in solid organ transplant recipients, 27 classifies patients' level of adjustment in 10 aspects of psychosocial functioning: current or past psychiatric diagnoses (Axis I and II), substance use/abuse, compliance, health behaviors, quality of family/social support, prior history of coping, coping with disease and treatment, quality of affect and mental status. This instrument has been shown to have clinical utility for specifying behavioral concerns before BMT as well as guiding interventions after transplantation. 28 It also has high inter-rater reliability (r ¼ 0.89) and internal consistency. 29 It is therefore suggested as a useful scale for both routine clinical use, ensuring that relevant aspects of psychosocial functioning are considered, as well as an instrument for future research in this area.
The Alcohol Use Disorders Identification Test (AUDIT) (The AUDIT questionnaire and manual with guidelines for use are available online at www.who.org.) developed by the World Health Organization 30 is an excellent tool to accurately assess a patient's use of alcohol over the past year. This instrument assesses three domains of alcoholism:
(1) hazardous alcohol use (frequency of drinking, typical quantity and frequency of heavy drinking), (2) dependence symptoms (impaired control over drinking, increased salience of drinking, morning drinking) and (3) harmful sequelae of alcohol use (guilt after drinking, blackouts, alcohol-related injuries and others concerned about drinking). This instrument can be self-administered, which may improve a patient's self-disclosure of alcohol use, and can also be incorporated into a clinical interview. A score of 8 or more for men up to 60 years of age, and 4 or more for In some clinical situations, such as cases in which the disease is slow growing and transplant is not imperative and/or when other treatment is needed before transplantation, we strongly advise that a referral be made to an addiction medicine specialist and chemical dependency treatment is begun before transplantation is offered. For those patients who require HSCT immediately, it is recommended that consultation be obtained with an addiction medicine specialist and/or psychiatist with experience in addiction during the patient's hospital stay. This collaboration can serve to address both the management of acute withdrawal, if needed, and institute psychotherapeutic, educational and medical modalities to begin the recovery process. 31 Referral for ongoing chemical dependency treatment should be made once the patient is stable enough, medically, to participate in an addiction recovery program (Figure 1 ).
Future considerations
Multicenter collaboration with regard to assessment and follow-up of patients with addictive disorders undergoing HSCT would be helpful in clarifying the impact of SUDs on morbidity and mortality. Partnership among National Cancer Institute-designated cancer centers to collect data regarding both medical and psychosocial morbidity as well as survival outcomes is suggested, utilizing the instruments as described above.
For the individual patient, close multidisciplinary teamwork that includes addiction medicine specialists, psychiatrists and social workers collaborating together with the medical oncology team is essential to provide the best possible treatment and outcomes for these complex patients.
